Difference between revisions of "High-grade glioma, pediatric"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.nccn.org/professionals/physician_gls/pdf/ped_cns.pdf" to "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509") |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
(4 intermediate revisions by the same user not shown) | |||
Line 4: | Line 4: | ||
</div> | </div> | ||
{{#lst:Editorial board transclusions|peds-neuro}} | {{#lst:Editorial board transclusions|peds-neuro}} | ||
− | + | ''This page contains studies that are specific to pediatric populations. | |
*For the more general '''high-grade glioma''' category page, follow '''[[:Category:High-grade_gliomas|this link]]'''. | *For the more general '''high-grade glioma''' category page, follow '''[[:Category:High-grade_gliomas|this link]]'''. | ||
− | *For '''pediatric low-grade glioma (pLGG)''', follow '''[[Low-grade glioma, pediatric|this link]]'''. | + | *For '''pediatric low-grade glioma (pLGG)''', follow '''[[Low-grade glioma, pediatric|this link]]'''. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 15: | Line 15: | ||
=Guidelines= | =Guidelines= | ||
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
− | == | + | ==NCCN== |
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509 NCCN Guidelines - Pediatric Central Nervous System Cancers] | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509 NCCN Guidelines - Pediatric Central Nervous System Cancers] | ||
=Adjuvant therapy= | =Adjuvant therapy= | ||
Line 51: | Line 51: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''HERBY:''' Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. Epub 2018 Feb 7. [https://doi.org/10.1200/JCO.2017.76.0611 link to original article] ''' | + | #'''HERBY:''' Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. Epub 2018 Feb 7. [https://doi.org/10.1200/JCO.2017.76.0611 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29412784/ PubMed] [https://clinicaltrials.gov/study/NCT01390948 NCT01390948] |
==VCP {{#subobject:f7dcb5|Regimen=1}}== | ==VCP {{#subobject:f7dcb5|Regimen=1}}== | ||
Line 85: | Line 85: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''CCG-945:''' Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. [https://doi.org/10.1200/JCO.1995.13.1.112 link to original article] ''' | + | #'''CCG-945:''' Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. [https://doi.org/10.1200/JCO.1995.13.1.112 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/7799011/ PubMed] |
==Vincristine & RT {{#subobject:f7drt5|Regimen=1}}== | ==Vincristine & RT {{#subobject:f7drt5|Regimen=1}}== | ||
Vincristine & RT: Vincristine & '''<u>R</u>'''adiation '''<u>T</u>'''herapy | Vincristine & RT: Vincristine & '''<u>R</u>'''adiation '''<u>T</u>'''herapy | ||
Line 121: | Line 121: | ||
===References=== | ===References=== | ||
− | #'''CCG-945:''' Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. [https://doi.org/10.1200/JCO.1995.13.1.112 link to original article] ''' | + | #'''CCG-945:''' Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. [https://doi.org/10.1200/JCO.1995.13.1.112 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/7799011/ PubMed] |
=Recurrent disease, non-curative therapy, non-randomized or retrospective data= | =Recurrent disease, non-curative therapy, non-randomized or retrospective data= | ||
Line 161: | Line 161: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [https://doi.org/10.1002/cncr.22961 link to original article] ''' | + | #Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [https://doi.org/10.1002/cncr.22961 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17705175/ PubMed] |
[[Category:High-grade glioma regimens]] | [[Category:High-grade glioma regimens]] |
Latest revision as of 12:22, 15 July 2024
Section editor | |
---|---|
Nicole M. Wood, DO University of Missouri Kansas City, MO, USA |
This page contains studies that are specific to pediatric populations.
- For the more general high-grade glioma category page, follow this link.
- For pediatric low-grade glioma (pLGG), follow this link.
4 regimens on this page
5 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
Adjuvant therapy
Temozolomide & RT
Temozolomide & RT: Temozolomide & Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Grill et al. 2018 (HERBY) | 2011-2015 | Randomized Phase 2 (C) | Temozolomide, Bevacizumab, RT | Did not meet primary endpoint of EFS |
Preceding treatment
Chemotherapy
- Temozolomide (Temodar) as follows:
- Cycle 1 (chemoradiation): 75 mg/m2 PO or IV once per day on days 1 to 42
- Cycles 2 to 13: 150 to 200 mg/m2 PO once per day on days 1 to 5
Radiotherapy
- Concurrent radiation therapy as follows:
- Cycle 1: 180 cGy fractions x 30 fractions, for a total dose of 5400 cGy
10-week course, then 28-day cycle for up to 12 cycles
References
- HERBY: Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. Epub 2018 Feb 7. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01390948
VCP
VCP: Vincristine, CCNU (Lomustine), Prednisone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Finlay et al. 1995 (CCG-945) | 1985-1990 | Phase 3 (C) | 8-drug regimen | Did not meet primary endpoint of OS |
Note: the exact schedule of vincristine is impossible to discern from Figure 1.
Preceding treatment
- Surgery, then adjuvant Vincristine & RT
Chemotherapy
- Lomustine (CCNU) 100 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 14
42-day cycle for 8 cycles
References
- CCG-945: Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Vincristine & RT
Vincristine & RT: Vincristine & Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Finlay et al. 1995 (CCG-945) | 1985-1990 | Phase 3 (C) | 8-drug regimen | Did not meet primary endpoint of OS |
Preceding treatment
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64
Radiotherapy
- Concurrent radiation therapy
70-day course
Subsequent treatment
- Adjuvant VCP
References
- CCG-945: Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Recurrent disease, non-curative therapy, non-randomized or retrospective data
Temozolomide monotherapy
Regimen variant #1, no radiation history
Study | Dates of enrollment | Evidence |
---|---|---|
Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 150 to 200 mg/m2 PO once per day on days 1 to 5
- Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 11 cycles
Regimen variant #2, previous craniospinal irradiation (CSI)
Study | Dates of enrollment | Evidence |
---|---|---|
Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 11 cycles
References
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article dosing details in manuscript have been reviewed by our editors PubMed